CRSP250103P52000
- 6.33
- 0.000.00%
CRISPR Therapeutics Newsroom
Cathie Wood's ARK Innovation ETF Couldn't Keep Up in 2024
CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
Institutional Investors May Adopt Severe Steps After CRISPR Therapeutics AG's (NASDAQ:CRSP) Latest 8.3% Drop Adds to a Year Losses
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
1 Big New Green Flag for CRISPR Therapeutics' Stock
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
3 Things You Need to Know If You Buy CRISPR Therapeutics Today
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target
CRISPR Therapeutics Analyst Ratings
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Vertex Reports Positive Long-term Data for Casgevy